ClinicalTrials.Veeva

Menu

Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP (PALATIN)

National Taiwan University logo

National Taiwan University

Status

Enrolling

Conditions

Plasmapheresis
Amyotrophic Lateral Sclerosis

Treatments

Procedure: Plasmapheresis

Study type

Interventional

Funder types

Other

Identifiers

NCT05562960
202202042DINC

Details and patient eligibility

About

Patient with amyotrophic lateral sclerosis (ALS) having anti-NRIP autoantibody showed titer-dependent detrimental Effects. Plasmapheresis might benefit this subgroup of patients via removal of anti-NRIP autoantibody

Enrollment

20 estimated patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Patients with amyotrophic lateral sclerosis (ALS) at the age more than 20 years and having plasma anti-NRIP autoantibody.
  2. Agree to receive plasmapheresis intervention.
  3. Agree to participate in the trial and receive serial examinations and follow up.

Exclusion criteria

  1. Patients without plasma anti-NRIP autoantibody.
  2. Patients requiring permanent ventilator support for ALS progression.
  3. Not able to receive plasmapheresis or trial-related examinations.
  4. Under pregnancy.
  5. Blood fibrinogen level less than 50 mg/dl.
  6. Specific ALS subtypes, including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

ALS patients receiving plasmapheresis
Other group
Description:
Plasmapheresis in ALS patients with different titers of autoantibody against NRIP
Treatment:
Procedure: Plasmapheresis

Trial contacts and locations

1

Loading...

Central trial contact

Li-Kai Tsai, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems